spacer
home > epc > winter 2019 > improving quality using centralised statistical monitoring
PUBLICATIONS
European Pharmaceutical Contractor

Improving Quality Using Centralised Statistical Monitoring

As the dust begins to settle after the ICH Good Clinical Practice E6 (R2) Addendum, the importance of data oversight and integrity should still not be overlooked. It has become increasingly important to the FDA after the Addendum and likewise for the sponsor’s responsibility to ensure quality management over regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Thomas Underwood, Marketing Manager at Quanticate, has over 10 years’ experience within the life sciences industry. Originally working in operations in both clinical data management and programming, he moved into the commercial division and has been in his current role for over eight years. An integral part of Thomas’ role is product development, involving extensive research into industry regulations and the resulting technology and services these influence, such as risk-based monitoring, data quality oversight, and centralised statistical monitoring. He has a postgraduate professional diploma with the Chartered Institute of Marketing and secured Chartered Marketer status in 2014.
spacer
Thomas Underwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services expands analytical Service Spectrum in Biosimilar Development Support

Heilbronn/Dortmund February 2019: The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients. To meet our customer demands now and in the future, PPS always invests in new analytical technique and recently added a new Differential Scanning Calorimetry (DSC) device.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement